Minimal Residual Disease Market
Minimal Residual Disease Market Forecasts to 2030 - Global Analysis By Offering (Hematological Malignancies and Solid Tumors), Sample Type, Clinical Utility, Technology, End User and By Geography
According to Stratistics MRC, the Global Minimal Residual Disease Market is accounted for $1.96 billion in 2024 and is expected to reach $4.51 billion by 2030 growing at a CAGR of 14.88% during the forecast period. Minimal Residual Disease (MRD) is an important marker in hematologic cancers like leukemia, lymphoma, and multiple myeloma. It helps doctors figure out how well treatment is working and make decisions about future care. Advanced techniques like flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS) enable highly sensitive detection of MRD, allowing for personalized treatment adjustments, early intervention, and improved long-term patient outcomes. Moreover, MRD is the small number of cancer cells that remain in a patient's body after treatment, which are undetectable through conventional imaging or laboratory tests but can still cause relapse.
According to BD Biosciences, MRD is a crucial biomarker in clinical trials for blood cancers such as acute lymphoblastic leukemia and multiple myeloma, with sensitivity and specificity values often exceeding 95%.
Market Dynamics:
Driver:
Increasing personalized medicine adoption
The need for MRD testing is growing as precision oncology becomes more prevalent. MRD tests enable individualized treatment modifications by precisely identifying residual disease, such as lowering treatment intensity for patients with a low risk of relapse or increasing therapy for high-risk patients. This method reduces the negative effects and financial burden of needless treatments while also improving patient outcomes. Additionally, the market is expanding as a result of MRD testing's incorporation into precision medicine frameworks.
Restraint:
Expensive MRD testing
The high expense of MRD testing is one of the main obstacles preventing its widespread use. Advanced methods like digital PCR, multi-parameter flow cytometry, and next-generation sequencing (NGS) are costly because they call for specialized equipment, chemicals, and skilled workers. Depending on the technology employed and the quantity of markers examined, MRD testing can cost anywhere from hundreds to thousands of dollars per test. Affordability is still a problem for healthcare systems with little funding, especially in developing nations. Furthermore, regular MRD monitoring for cancer patients receiving long-term therapy raises costs even more and restricts access.
Opportunity:
Extension of MRD examination in solid cancers
The use of minimal residual disease (MRD) testing in solid tumors offers a substantial growth opportunity, despite the fact that it has been extensively adopted in hematologic malignancies. A promising method for identifying MRD in solid tumors like prostate, colorectal, lung, and breast cancers is circulating tumor DNA (ctDNA) analysis. In contrast to conventional imaging methods, ctDNA-based MRD detection enables earlier intervention by detecting molecular recurrence before tumors appear on scans. Moreover, research and commercial expansion into new cancer types are being fueled by investments made in MRD assays for solid tumors by companies such as Foundation Medicine, Natera, and Guardant Health.
Threat:
Tough regulatory conditions
MRD testing is subject to strict regulatory oversight, as its clinical applications involve critical cancer treatment decisions. Before approving MRD assays, regulatory bodies like the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and other international health authorities demand thorough clinical validation. The lengthy and expensive regulatory approval process can postpone new products' release onto the market. Additionally, businesses looking to expand internationally face compliance issues due to regional differences in regulatory frameworks. Product recalls, penalties, or limitations on market access may arise from noncompliance with changing regulatory requirements.
Covid-19 Impact:
The COVID-19 pandemic had a mixed effect on the market for minimal residual disease (MRD). At first, lockdowns and overburdened healthcare systems disrupted clinical trials, cancer screenings, and diagnostic procedures. Testing volumes decreased as a result of the deprioritization or delay of numerous non-urgent cancer monitoring tests, such as MRD evaluations. But the pandemic also spurred interest in non-invasive MRD detection techniques like circulating tumor DNA (ctDNA) analysis by speeding up developments in remote monitoring, liquid biopsy adoption, and decentralized clinical trials. Furthermore, the significance of MRD testing has also been reaffirmed by the post-pandemic increased focus on precision medicine and oncology research, which has resulted in new investments, regulatory support, and technological developments that propel market expansion.
The Assay Kits & Reagents segment is expected to be the largest during the forecast period
The Assay Kits & Reagents segment is expected to account for the largest market share during the forecast period. These assay kits and reagents are necessary for methods that are frequently employed in MRD testing, including flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). Their recurrent nature guarantees ongoing use in hospitals, research facilities, and diagnostic labs, supporting their continued market dominance. Moreover, this segment's growth is further fueled by developments in highly sensitive and specific reagents for detecting traces of remaining cancer cells, which makes it a significant source of revenue for the MRD market.
The Treatment Response Assessment segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Treatment Response Assessment segment is predicted to witness the highest growth rate. The growing use of MRD testing to assess the efficacy of immunotherapy’s, targeted therapies, and chemotherapy regimens is what is driving this market. Clinicians can now modify treatment in real time based on MRD status thanks to developments in digital PCR and next-generation sequencing (NGS), which enhances patient outcomes and lowers needless treatment toxicity. Additionally, growth in this market is also being fueled by regulatory approvals for MRD as a biomarker in clinical trials and drug development, which is speeding up its incorporation into oncology treatment protocols.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, driven by advanced healthcare infrastructure, high adoption of precision medicine, and strong investments in cancer research. The area benefits from a high incidence of hematologic malignancies, reputable diagnostic labs, and easy access to state-of-the-art technologies like digital PCR for MRD detection and next-generation sequencing (NGS). Furthermore, the U.S. FDA's supportive regulations, the rise in clinical trials using MRD as a biomarker, and the expansion of pharmaceutical and diagnostic company partnerships all contribute to North America's market dominance in MRD.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR because of the increased incidence of cancer, the development of better healthcare facilities, and the growing use of cutting-edge diagnostic tools. The need for MRD testing is being driven by significant investments being made in precision medicine and oncology research by nations like China, India, and Japan. Moreover, the market is also growing faster due to government initiatives to improve cancer diagnostics, rising healthcare spending, and increased awareness of early cancer detection. Increased partnerships between foreign diagnostic firms and regional healthcare providers are also taking place in the area, which will increase MRD technology adoption and accessibility.
Key players in the market
Some of the key players in Minimal Residual Disease market include Adaptive Biotechnologies Corporation, F. Hoffmann-La Roche Ltd, Natera Inc., Guardant Health, QIAGEN N.V., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Sysmex Corporation, NeoGenomics Inc., Illumina Inc., Thermo Fisher Scientific Inc., Bio-Techne Corporation, Invitae Corporation, Invivoscribe Inc., Quest Diagnostics, PerkinElmer Inc., Agilent Technologies Inc. and Laboratory Corporation of America Holdings.
Key Developments:
In February 2025, Bio-Rad Laboratories, Inc launched its TrailBlazer Tag and TrailBlazer StarBright Dye Label Kits. The new kits are designed to offer a convenient method to label any antibody with one of Bio-Rad’s StarBright Dyes, for use in either flow cytometry or fluorescent western blot experiments.
In November 2024, Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc., a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Poseida’s R&D portfolio includes pre-clinical and clinical-stage off-the-shelf CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms.
In March 2024, Sysmex Corporation and CellaVision AB will be working together to advance hematology solutions by expanding its portfolio, including next-generation cell morphology analyzers. Going forward, the companies will work to further increase efficiency and standardization of the testing workflow in the hematology field, increase the precision of cell morphology classification, and provide value in supporting diagnosis.
Offerings Covered:
• Assay Kits & Reagents
• Instruments/Platforms
• Software/Data Analysis Solutions
• Services
Disease Types Covered:
• Hematological Malignancies
• Solid Tumors
Sample Types Covered:
• Blood
• Bone Marrow
• Other Sample Types
Clinical Utilities Covered:
• MRD Monitoring & Detection
• Treatment Response Assessment
• Prognosis & Risk Stratification
Technologies Covered:
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Fluorescence In Situ Hybridization (FISH)
• Mass Spectrometry
End Users Covered:
• Hospitals & Specialty Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotech Companies
• Contract Research Organizations (CROs)
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Minimal Residual Disease Market, By Offering
5.1 Introduction
5.2 Assay Kits & Reagents
5.3 Instruments/Platforms
5.4 Software/Data Analysis Solutions
5.5 Services
6 Global Minimal Residual Disease Market, By Disease Type
6.1 Introduction
6.2 Hematological Malignancies
6.2.1 Leukemia
6.2.2 Lymphoma
6.2.3 Multiple Myeloma
6.2.4 Myelodysplastic Syndromes (MDS)
6.3 Solid Tumors
6.3.1 Breast Cancer
6.3.2 Colorectal Cancer
6.3.3 Lung Cancer
6.3.4 Other Solid Tumors
7 Global Minimal Residual Disease Market, By Sample Type
7.1 Introduction
7.2 Blood
7.3 Bone Marrow
7.4 Other Sample Types
8 Global Minimal Residual Disease Market, By Clinical Utility
8.1 Introduction
8.2 MRD Monitoring & Detection
8.3 Treatment Response Assessment
8.4 Prognosis & Risk Stratification
9 Global Minimal Residual Disease Market, By Technology
9.1 Introduction
9.2 Flow Cytometry
9.3 Polymerase Chain Reaction (PCR)
9.3.1 Quantitative PCR (qPCR)
9.3.2 Digital PCR (dPCR)
9.4 Next Generation Sequencing (NGS)
9.5 Fluorescence In Situ Hybridization (FISH)
9.6 Mass Spectrometry
10 Global Minimal Residual Disease Market, By End User
10.1 Introduction
10.2 Hospitals & Specialty Clinics
10.3 Diagnostic Laboratories
10.4 Academic & Research Institutes
10.5 Pharmaceutical & Biotech Companies
10.6 Contract Research Organizations (CROs)
11 Global Minimal Residual Disease Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Adaptive Biotechnologies Corporation
13.2 F. Hoffmann-La Roche Ltd
13.3 Natera Inc.
13.4 Guardant Health
13.5 QIAGEN N.V.
13.6 Bio-Rad Laboratories Inc.
13.7 Exact Sciences Corporation
13.8 Sysmex Corporation
13.9 NeoGenomics Inc.
13.10 Illumina Inc.
13.11 Thermo Fisher Scientific Inc.
13.12 Bio-Techne Corporation
13.13 Invitae Corporation
13.14 Invivoscribe Inc.
13.15 Quest Diagnostics
13.16 PerkinElmer Inc.
13.17 Agilent Technologies Inc.
13.18 Laboratory Corporation of America Holdings
List of Tables
1 Global Minimal Residual Disease Market Outlook, By Region (2022-2030) ($MN)
2 Global Minimal Residual Disease Market Outlook, By Offering (2022-2030) ($MN)
3 Global Minimal Residual Disease Market Outlook, By Assay Kits & Reagents (2022-2030) ($MN)
4 Global Minimal Residual Disease Market Outlook, By Instruments/Platforms (2022-2030) ($MN)
5 Global Minimal Residual Disease Market Outlook, By Software/Data Analysis Solutions (2022-2030) ($MN)
6 Global Minimal Residual Disease Market Outlook, By Services (2022-2030) ($MN)
7 Global Minimal Residual Disease Market Outlook, By Disease Type (2022-2030) ($MN)
8 Global Minimal Residual Disease Market Outlook, By Hematological Malignancies (2022-2030) ($MN)
9 Global Minimal Residual Disease Market Outlook, By Leukemia (2022-2030) ($MN)
10 Global Minimal Residual Disease Market Outlook, By Lymphoma (2022-2030) ($MN)
11 Global Minimal Residual Disease Market Outlook, By Multiple Myeloma (2022-2030) ($MN)
12 Global Minimal Residual Disease Market Outlook, By Myelodysplastic Syndromes (MDS) (2022-2030) ($MN)
13 Global Minimal Residual Disease Market Outlook, By Solid Tumors (2022-2030) ($MN)
14 Global Minimal Residual Disease Market Outlook, By Breast Cancer (2022-2030) ($MN)
15 Global Minimal Residual Disease Market Outlook, By Colorectal Cancer (2022-2030) ($MN)
16 Global Minimal Residual Disease Market Outlook, By Lung Cancer (2022-2030) ($MN)
17 Global Minimal Residual Disease Market Outlook, By Other Solid Tumors (2022-2030) ($MN)
18 Global Minimal Residual Disease Market Outlook, By Sample Type (2022-2030) ($MN)
19 Global Minimal Residual Disease Market Outlook, By Blood (2022-2030) ($MN)
20 Global Minimal Residual Disease Market Outlook, By Bone Marrow (2022-2030) ($MN)
21 Global Minimal Residual Disease Market Outlook, By Other Sample Types (2022-2030) ($MN)
22 Global Minimal Residual Disease Market Outlook, By Clinical Utility (2022-2030) ($MN)
23 Global Minimal Residual Disease Market Outlook, By MRD Monitoring & Detection (2022-2030) ($MN)
24 Global Minimal Residual Disease Market Outlook, By Treatment Response Assessment (2022-2030) ($MN)
25 Global Minimal Residual Disease Market Outlook, By Prognosis & Risk Stratification (2022-2030) ($MN)
26 Global Minimal Residual Disease Market Outlook, By Technology (2022-2030) ($MN)
27 Global Minimal Residual Disease Market Outlook, By Flow Cytometry (2022-2030) ($MN)
28 Global Minimal Residual Disease Market Outlook, By Polymerase Chain Reaction (PCR) (2022-2030) ($MN)
29 Global Minimal Residual Disease Market Outlook, By Quantitative PCR (qPCR) (2022-2030) ($MN)
30 Global Minimal Residual Disease Market Outlook, By Digital PCR (dPCR) (2022-2030) ($MN)
31 Global Minimal Residual Disease Market Outlook, By Next Generation Sequencing (NGS) (2022-2030) ($MN)
32 Global Minimal Residual Disease Market Outlook, By Fluorescence In Situ Hybridization (FISH) (2022-2030) ($MN)
33 Global Minimal Residual Disease Market Outlook, By Mass Spectrometry (2022-2030) ($MN)
34 Global Minimal Residual Disease Market Outlook, By End User (2022-2030) ($MN)
35 Global Minimal Residual Disease Market Outlook, By Hospitals & Specialty Clinics (2022-2030) ($MN)
36 Global Minimal Residual Disease Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
37 Global Minimal Residual Disease Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
38 Global Minimal Residual Disease Market Outlook, By Pharmaceutical & Biotech Companies (2022-2030) ($MN)
39 Global Minimal Residual Disease Market Outlook, By Contract Research Organizations (CROs) (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
